PO Box 4214
Morgantown, West Virginia 26504
Phone 304-212-2616

Our Focus

The West Virginia Chapter of the National Hemophilia Foundation, WVNHF, provides education, support, awareness, and advocacy for the bleeding disorder community. 

We are the leading resource for West Virginians affected by bleeding disorders. You can count on us to ensure your voice is heard. It’s with your help that we can make a difference. Learn more and get involved.

News Articles

On November 22, the U.S. Food and Drug Administration approved Hemgenix (etranacogene dezaparvovec), an adeno-associated virus (AAV) vector-based gene therapy. It is approved for the treatment of adults with hemophilia B who currently use factor IX (FIX) prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.

Historically, many residential substance use disorder (SUD) facilities have denied admittance to individuals with bleeding disorders – the basis of these denials are most often the use of self-administered, intravenous medications such a as factor replacement therapies.


Advertisement

Click to learn more.

PO Box 4214
Morgantown, West Virginia 26504
Phone 304-212-2616

© West Virginia Chapter National Hemophilia Foundation 2022

Crafted by Firespring